Cencora — Feb 5, 2025 release

The Company now expects: • Revenue growth to be in the range of 8 to 10 percent, from the previous range of 7 to 9 percent; ◦ U.S. Healthcare Solutions revenue growth to be in the range of 9 to 11 percent, from the previous range of 7 to 9 percent; ◦ International Healthcare Solutions revenue growth to be in the range of 4 to 5 percent, from the previous range of 7 to 9 percent; • Adjusted diluted EPS to be in the range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45 provided on January 2, 2025 and the initial guidance range of $14.80 to $15.10. Additional expectations now include: • Adjusted consolidated operating income growth to be in the range of 11.5 to 13.5 percent, from the previous range of 5 to 6.5 percent; ◦ U.S. Healthcare Solutions segment operating income growth to be in the range of 14.5 to 16.5 percent, from the previous range of 5 to 6.5 percent; ◦ International Healthcare Solutions segment as reported operating income growth to be flat, from the previous range of 5 to 6.5 percent; ▪ On a constant currency basis, International Healthcare Solutions segment operating income growth to be approximately 5 percent; • Net interest expense to be in the range of $290 million to $310 million, from the previous range of $150 million to $170 million; and • Weighted average diluted shares outstanding is expected to be under 196 million, from the previous expectation of approximately 196 million. For additional details regarding updated guidance expectations on a constant currency basis, pl